Abstract Emerging evidence suggests that probiotic therapy can play a role in the prevention and management of oral inflammatory diseases through immunomodulation and downregulation of the inflammatory cascade. The aim of this in vitro study was to investigate the viability of human gingival fibroblasts (HGF) and its production of prostaglandin E 2 (PGE 2 ), when exposed to supernatants of two mixed Lactobacillus reuteri strains (ATCC PTA 5289 and DSM 17938). The experiments were conducted in the presence and absence of the proinflammatory cytokine IL-1β. L. reuteri strains were grown and the bacterial supernatant was collected. The cell-free supernatant was diluted to concentrations equivalent to the ones produced by 0.5 to 5.0 × 10 7 CFU/mL bacteria. Cell viability was assessed with the MTT colorimetric assay and the amount of PGE 2 in the cell culture medium was determined using the monoclonal enzyme immune assay kits. Our findings showed that none of the L. reuteri supernatants were cytotoxic or affected the viability of HGF. The most concentrated bacterial supernatant stimulated the production of PGE 2 by the gingival cells in a significant way in the presence of IL-1β (p < 0.05), suggesting that bacterial products secreted from L. reuteri might play a role in the resolution of inflammation in HGF. Thus, our findings justify further investigations on the influence of probiotic bacteria on gingival inflammatory reactions.
Introduction
There is an emerging interest to use probiotic bacteria for the prevention and management of chronic inflammatory diseases in the oral cavity, such as gingivitis and periodontitis. Recent systematic reviews support the use of probiotic supplements as an adjunct to traditional oral hygiene, scaling, and root planning [1] [2] [3] . The beneficial effects are likely mediated through immunomodulation, as supported by the evidence of a downregulation of the inflammatory cascade in gingival crevicular fluid (GCF) following intervention with probiotic bacteria [4] [5] [6] . Less is however known about the effect of probiotics for the management of acute oral inflammatory conditions, such as mucositis, aphthous stomatitis, and the healing of surgical wounds. In that context, a low-grade inflammation is a prerequisite to trigger further immune reactions leading to tissue remodeling and wound closure. Previous research has indicated that probiotic lactobacilli can enhance IgA concentration in saliva [7] and stimulate a low-grade inflammation beneficial for tissue repair [8] . For example, consumption of Lactobacillus reuteri has improved dermal tissue repair in mice [9] but, to the best of our knowledge, information of a potential effect in the human oral mucosa is lacking.
Fibroblasts are the major cells in the oral mucosa and are responsible for the secretion of several immune-modulating cytokines and inflammatory mediators of importance for tissue repair [10] . One of these mediators is prostaglandin E 2 (PGE 2 ), a major cyclooxygenase-2 (COX-2) product. PGE 2 plays a key role in inflammation and in wound healing and is known for modulating cell proliferation, including that of fibroblasts [11, 12] . During tissue injury, the pro-inflammatory cytokine interleukin-1β (IL-1β) produced by keratinocytes and immune cells activates fibroblasts and induces PGE 2 production [13, 14] . High levels of IL-1β are observed in connection to chronic unresolved wounds [15] , and it is well established that in subjects with clinical gingivitis, cells from the oral mucosa are capable of elevating both IL-1β and PGE 2 in GCF [16] . Bacteria per se can induce the synthesis of PGE 2 [17] , and the induction of a low-grade/moderate inflammation might improve the outcomes of acute inflammatory processes [8] . Following this logic, supernatants of the genera Lactobacillus have been tested for its ability to stimulate inflammation and accelerate wound healing [18, 19] . In this communication, we aimed at determining if there is an inflammatory response in HGF when exposed to L. reuteri bacterial products, by investigating (i) the viability of human gingival fibroblasts (HGF) exposed to a mix of bacterial supernatants from two L. reuteri strains (ATCC PTA 5289 and DSM 17938) and (ii) the production of PGE 2 in HGF cultures exposed to the cell-free bacterial supernatants in the presence or absence of the pro-inflammatory cytokine IL-1β.
Materials and Methods
Gingival Fibroblasts Culture A primary culture of human gingival fibroblasts was established from the gingival tissue biopsy of healthy donors with no clinical signs of periodontal disease. The Regional Ethical Board in Stockholm approved the collection of biopsies and the establishment of the fibroblast cell lines (Dnr 377/98) as described previously [20] . Minced pieces of the gingival tissue were explanted to a 25-cm 2 tissue culture flask (Corning®, Sigma-Aldrich, St. Louis, MO, USA) containing 5 ml of DMEM-Dulbecco's modified Eagle's medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with penicillin (50 μg/ml), streptomycin (50 μg/ml), and 5% fetal calf serum (Gibco™, Thermo Fisher Scientific, Waltham, MA USA). Gingival fibroblasts obtained by trypsinisation of the primary cell outgrowth were grown in a humidified incubator at 37°C gassed with 5% CO 2. When 90% confluence was reached, cells were routinely passaged, using TrypLE™ (Thermo Fisher Scientific, Waltham, MA USA) for the enzymatic dissociation of the extracellular matrix. Human gingival fibroblasts between the 11th and 13th passages were used in the experiments.
Bacteria Cultures and Bacterial Supernatants L. reuteri strains DSM 17938 and ATCC PTA 5289, obtained from BioGaia AB, Sweden, were grown in MRS (de Man, Rogosa and Sharpe) medium (Sigma-Aldrich, St. Louis, MO, USA) up to mid-logarithmic growth phase (6 h) at 37°C. As both the MRS broth and a highly concentrated supernatant are cytotoxic for HGF, when bacteria reached 0.5 × 10 9 CFU/ml, MRS broth was removed and bacterial growth continued in DMEM for 4 h, following the protocol reported by Griet et al., 2014 [19] . The medium was centrifuged and the separated supernatant was aseptically filtered using 0.02-μm pore-size lowprotein-binding cellulose acetate filters (0.02 μm Filterpur S, Sarstedt AG & Co., Nümbrecht, Germany) to obtain a bacterial cell-free supernatant. The bacterial cell-free supernatants from each strain (pH 7.0) were mixed in 1:1 proportion and kept frozen at −20°C. For each independent experiment, the mix was thawed and four dilutions of the supernatant were prepared (corresponding to the supernatant produced by 0. ) were seeded in 96-well plates and allowed to attach and grow for 48 h. Then, cells were rinsed twice with serumfree DMEM and thereafter treated with or without different dilutions of the mixed bacterial supernatants in serum-free media for 24 h, in the presence or absence of the IL-1β (0.5 ng/mL). One hour before the viability assay, 5% saponin (Sigma-Aldrich, St. Louis, MO, USA) diluted in PBS with calcium and magnesium was added to one well in triplicate as a positive control for cell death. Cell proliferation was indirectly tested by the MTT assay, which is based on the cellular reduction of tetrazolium salts by NAD(P)H-dependent oxidoreductases. A commercial MTT kit was used (TACS® MTT Cell Proliferation Assay Kit, Trevigen®, Trevigen Inc., Gaithersburg, MD, USA) and the cell proliferation assay was performed according to the manufacturer's instructions. Ten microliters of MTT reagent was added to each well and the cells were incubated in the dark for 2 h at 37°C in a 5% CO 2 -humidified incubator to allow for intracellular reduction of the soluble MTT to the insoluble formazan dye. Then, 100 μL of detergent reagent containing sodium dodecyl sulfate (SDS) was added to allow formazan solubilization during 4 h at 37°C. The absorbance was measured at 620 nm using a microplate reader (Thermo/Labsystem Multiskan MS, Thermo Fisher Scientific, Waltham, MA USA).
Measurement of PGE 2 HGF cells (4 × 10 4 ) were seeded in 24-well plates and allowed to attach and grow for 48 h. The cell monolayers were rinsed twice with serum-free DMEM, followed by the addition of DMEM containing the inflammatory mediator IL-1β (0.5 ng/mL), alone or in combination with different dilutions of the mixed L. reuteri supernatants (corresponding to the supernatant produced by 0. After an incubation period of 24 h, the medium was removed and stored at −20°C. The amount of PGE 2 in cell culture medium was determined using the PGE 2 monoclonal enzyme immune assay kit (Cayman chemical, Ann Arbor, MI, USA) according to the manufacturer's instructions. The detection limit for the PGE 2 kit was 15 pg/mL.
Statistical Methods
Data were subjected to comparison of means (t test) using the MedCalc Statistical Software version 16.2.0 (MedCalc Software bvba, Ostend, Belgium). A p value less than 0.05 was considered statistically significant.
Results

Cell Viability
The effect of supernatants from the two L reuteri strains on the viability of human gingival fibroblasts is summarized in Fig. 1 . None of the tested concentrations (supernatant corresponding to 0.5-5.0 × 10 7 CFU/mL) affected the viability of HGF in contrast to the nonionic surfactant saponin used as positive control for cell death. The stimulation of the cells with IL-1β did not significantly affect the outcome.
PGE 2 Production
The effect of the mixed L reuteri supernatants on the PGE 2 production, alone or in combination with the proinflammatory cytokine IL-1β, is presented in Fig. 2 . We found that all tested concentrations of the supernatant (except one) tended to increase the PGE 2 production to various degrees in the presence of IL-1β. The most marked effect was obtained with the 5.0 × 10 7 dilution for which a 73% increase was noted compared to the IL-1β stimulation alone. This difference was statistically significant (p < 0.05). The PGE 2 production was also enhanced by the probiotic supernatant in the absence of IL-1β (283 vs. 155 pg/mL) but this difference did not reach statistical significance. The COX-2 inhibitor celecoxib inhibited the pro-inflammatory effect of IL-1β.
Discussion
This study was performed to investigate the possible influence of probiotic therapy on cell viability and inflammation as a first step to evaluate a possible beneficial impact on oral wound healing. The novel findings were that the L. reuteri supernatants did not seem to negatively affect, or damage, the cell viability of gingival fibroblasts and that the bacterial , and 5.0 × 10 7 CFU/mL). Control cells were not treated with L. reuteri supernatants. Treatment with saponin was used as a positive control for cell death. Cells were also stimulated with the COX-2 selective non-steroidal anti-inflammatory drug celecoxib (1 μM). Results are presented as means (SD) from triplicates of three independent experiments exposure could enhance the production of PGE 2 . In this context, it is important to underline that the highest concentration of the two bacterial supernatants (corresponding to 5.0 × 10 7 CFU/mL) seemed to increase PGE 2 production without affecting the cell viability. In agreement with our findings, a similar activation of the inflammatory response in mouse fibroblasts by Lactobacillus casei supernatants has been previously reported [18] . Although limited clinical conclusions can be drawn from in vitro findings, it seems possible that the present L. reuteri strains may moderate gingival reactions following acute stimuli.
Most in vitro studies attempting to unveil the mechanisms behind the clinical effects of probiotics employ a single strain but we used the supernatants from two strains of L. reuteri (ATCC PTA 5289 and DSM 17938) originally isolated from the oral cavity and breast milk, respectively. The rational for using this mix was pure pragmatic as the two strains are combined in a commercial product (BioGaia ProDentis) containing at least 1.0 × 10 8 live bacteria of each strain. The effects of these lozenges have been evaluated in several clinical trials and there is evidence of an ability to improve clinical signs of gingivitis and periodontitis [2] . The strains can be detected in the oral biofilm and saliva in 65-70% of subjects during regular consumption of lozenges [21] and once harbored, bacterial products are likely released to initiate both local and systemic events [22] . Although the mixed bacterial supernatants to some extent can mimic a clinical intervention, it seems of importance to further explore the strains one by one as the host effects likely are strain specific.
As bacterial components may be harmful for eukaryotic cells [23] , we first tested the viability of the HGF exposed to different concentrations of L. reuteri supernatant. According to the MTT assay, none of the dilutions affected the viability of the cells in a significant way. Since the MTT assay is based on the metabolic activity of the cells, changes in proliferation can also be calculated. In our experiments, the supernatant produced by 2.5 × 10 7 CFU of L. reuteri slightly stimulated cell proliferation, when compared to the controls. In an in vivo situation, this would be beneficial for the healing of wounds in the oral mucosa. Therefore, this tendency of L. reuteri strains to enhance cell proliferation merits further investigations, such as in vitro scratch assays.
In our present experiments, we employed the production of PGE 2 as a valid biomarker for inflammation in accordance with Yucel-Lindberg and co-workers [24] , and we stimulated the fibroblasts with IL-1β to simulate inflammatory processes affecting the cells. Our findings indicated a dose-related threshold concerning the PGE 2 production in cells stimulated with IL-1β, suggesting that the bacterial products from L. reuteri might potentiate acute inflammation in HGF. Zhao and co-workers [ 2 5 ] h a v e p r e v i o u s l y s h o w n t h a t p r e s e n c e o f Lactobacillus acidophilus can offset Porphyromonas gingivalis-induced secretion of interleukins by gingival epithelial cells in a dose-dependent manner. We have at present no explanation for this potential dose effect, but bacterial supernatants contain a complex mixture of biomolecules and metabolic products suspended in culture medium. These molecules may act as pathogenassociated molecular patterns (PAMPs), discrete patterns that are recognized by host cells through pattern recognition receptors (PRRs) [26] . Human gingival fibroblasts Results are presented as means (SD) from triplicates of three independent experiments. *P < 0.05 vs. IL-1β-stimulated cells are known to express all the range of toll-like receptors (TLRs), a group of highly conserved PRRs [27] . The PAMPs from the supernatants might bind to TLRs in HGF and thereby trigger a signaling cascade leading to the induction of the enzyme COX-2 and an increase in PGE 2 . At present, we do not know the identity of the molecule(s) responsible for the effect. The search for the actual effector molecules responsible for this inflammatory response requires further analyses, for example, through evaluation of fractions of the supernatant. We are also aware that several probiotic effector molecules might be present on the bacterial cell wall. Nevertheless, this study provides clear evidence of absence of any antiinflammatory effect in this experimental context.
Conclusion
The results of this in vitro study showed that mixed supernatants of two L. reuteri strains do not affect the viability of human gingival fibroblasts and suggests a dose-related effect on the inflammatory response. Thus, the findings justify further investigations on the impact of probiotic bacteria on gingival reactions to various stimuli as well as the healing of oral wounds.
